Navigation Links
Synthes and Kensey Nash Announce Strategic Agreement for Extracellular Matrix Products
Date:8/20/2009

s programs, Synthes' success in selling Kensey Nash's extracellular matrix products, the completion of additional clinical trials in both the U.S. and Europe to support regulatory approval of future generations of Kensey Nash's products and competition from other technologies.

In addition, changes in competitive conditions and regulatory developments may affect future business performance, and changing market conditions may affect the valuation of the Companies' securities. In addition, it should be noted that past financial and operational performance of the Companies is not necessarily indicative of future financial and operational performance.

The Companies undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

For a detailed discussion of factors that could affect Kensey Nash's future operating results, please see Kensey Nash's SEC filings, including the disclosure under "Risk Factors" in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

The securities of Synthes have been offered and sold outside the United States and have not been and will not be registered under the U.S. Securities Act of 1933, as amended ("Securities Act"). Such securities may not be offered, sold or transferred in the U.S. or to U.S. Persons (as defined in the regulations of the Securities Act), except pursuant to a registration statement filed under the Securities Act or under an applicable exemption under the Securities Act. Hedging transactions involving such securities may not be conducted unless in compliance with the Securities Act. The Synthes securities are deemed "Restricted Securities" as that term is defined in R
'/>"/>

SOURCE Kensey Nash Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Synthesis and Purification of Peptide Libraries -- Innovative Approaches
2. Register to Win a Ski Weekend and Make Your Synthesis Easier with EasyMax™: the First Automated Chemistry Development Tool That Requires No Training
3. Does Synthetic Biology Need Synthesized Ethics?
4. METTLER TOLEDO Introduces an Affordable Reaction Block for Solid Phase Peptide Synthesis (SPPS)
5. Sigma-Aldrich Enters Exclusive Supply Agreement With Gene Oracle to Leverage Its Unique GeneIOS Gene Synthesis Platform
6. 60 Specialty Chemical, Fine Chemical & Custom Synthesis Providers Will Exhibit at Pharma ChemOutsourcing on September 8-9 in New Jersey
7. Chromatide and Novasep Have Extended Their Partnership to Develop Large Scale Solid Phase Peptide and Oligonucleotide Synthesis Technology.
8. Sloning and the Kornberg group at Stanford University starting evaluation project regarding the synthesis of a Statistically Randomized Gene Library
9. Replikins Oral Vaccine Synthesized in 7 Days Protects 91% of Shrimp Against a Lethal Virus
10. Scientists synthesize memory in yeast cells
11. Scientists synthesize memory in yeast cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 02, 2015 , ... Spirax Sarco , ... to its eCommerce site Spirax Sarco Anytime. This platform, offering unique online ordering ... place your next order? Log on to Spirax Sarco Anytime and within minutes ...
(Date:9/1/2015)... , Sept. 1, 2015 Prostate ... death in American men. One in seven ... 233,000 new cases are diagnosed annually. That said, ... using a powerful new technique, MRI Fusion Biopsy, ... large cancer lesions, treating only the affected areas ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... recombinant antibodies, announced today that the National Institutes of Health (NIH) has awarded ... will be administered by the NIH’s National Institute of Diabetes and Digestive and ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... the neuro and pain management space join prominent academics and key investors for ... at Harvard Medical School in Boston. , Neuro Advance Boston focuses on ...
Breaking Biology Technology:Spirax Sarco Announces New Features to Anytime Platform 2September Is Prostate Cancer Awareness Month 2September Is Prostate Cancer Awareness Month 3September Is Prostate Cancer Awareness Month 4AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 2AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 3Neuro Advance Boston Brings Together Leading Neuroscience Experts on October 14 at Harvard Medical School 2
... (Nasdaq: NYER ) reported results for the fiscal year ... 30, 2008 increased $6.6,million or 10.2% to $71.2 million from ... for the fiscal year ended June 30, 2008 was,$403,520 or ... $86,446 or $.02,per share for the previous fiscal year., ...
... MirixaPro(SM) chosen to enable patient care services in Australia through ... ... NCPA 110th Annual Convention --,Mirixa Corporation, the leader in pharmacy-based ... of Australia, announced,today that they have signed a definitive technology ...
... (OTC,Pink Sheets: SNDY) is pleased to announce that the ... on the Pinksheets Electronic OTC Markets from,Limited Information to ... their Issuer Information Statement, which will be accompanied,by an ... status,upgraded by the end of the quarter., A ...
Cached Biology Technology:Nyer Medical Group, Inc. Reports Revenues of $71.2 Million With Net Loss of $.10 Per Share for Fiscal Year 2008 2Nyer Medical Group, Inc. Reports Revenues of $71.2 Million With Net Loss of $.10 Per Share for Fiscal Year 2008 3Mirixa Announces Agreement With the Pharmacy Guild of Australia 2Mirixa Announces Agreement With the Pharmacy Guild of Australia 3Solos Endoscopy, Inc. in Final Stages to Upgrade Pink Sheet Status from Limited to Current Information 2
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
(Date:8/6/2015)... , Aug. 6, 2015  Today, U.S. ... visit Crossmatch ™ to learn firsthand how ... protect data. Crossmatch is a world leader in ... and expertise are helping federal agencies and commercial ... security.   "The vast majority of ...
(Date:8/6/2015)... JOSE, Calif. , Aug. 6, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... TouchPad technologies on Windows 10. Microsoft leveraged Synaptics, ... to the operating system. Through ... drivers are fully certified with Microsoft,s Precision TouchPad ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... cancer,patients have an abnormality in a specific cell ... pathway may be,especially effective for treating the disease, ... D. Anderson Cancer Center.", , A clearer picture ... 3 kinase (PI3K),pathway to breast cancer development, says ...
... got updated to version 5.0. Proteins are classified,by ... known,pathways. Its main use is probably microarray analysis ... output. Best of,all, its available freely . ... freely in the Nucleic acids research Journal . ...
... An estrogen-like chemical,commonly used to synthesize plastic food ... a specific category of prostate cancer cell,potentially affecting ... to a study published in the January 1 ... to be vulnerable to,exposure to the chemical BPA ...
Cached Biology News:PANTHER Protein Classification System Database 5.0 2PANTHER Protein Classification System Database 5.0 3Estrogen-like Component of Plastic Stimulates Growth of Certain Prostate Cancer Cells 2
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
ANTI S. ENTERID LPS...
... This DuoSet ELISA Development kit contains the ... sandwich ELISAs to measure natural and recombinant ... serum. Each kit contains sufficient materials to ... provided that the following conditions are met: ...
... DuoSet ELISA Development kit contains the basic ... ELISAs to measure natural and recombinant rat ... Each kit contains sufficient materials to ... provided that the following conditions are met: ...
Biology Products: